KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Debt to Equity (2016 - 2023)

Pacific Biosciences Of California has reported Debt to Equity over the past 13 years, most recently at $0.13 for Q3 2023.

  • Quarterly results put Debt to Equity at $0.13 for Q3 2023, changed N/A from a year ago — trailing twelve months through Sep 2023 was $0.13 (changed N/A YoY), and the annual figure for FY2022 was $0.31, up 6105.92%.
  • Debt to Equity for Q3 2023 was $0.13 at Pacific Biosciences Of California, down from $0.29 in the prior quarter.
  • Over the last five years, Debt to Equity for PACB hit a ceiling of $0.31 in Q4 2022 and a floor of $0.0 in Q4 2021.
  • Median Debt to Equity over the past 4 years was $0.28 (2019), compared with a mean of $0.21.
  • Biggest five-year swings in Debt to Equity: soared 123.86% in 2019 and later surged 6105.92% in 2022.
  • Pacific Biosciences Of California's Debt to Equity stood at $0.29 in 2019, then crashed by 98.28% to $0.0 in 2021, then surged by 6105.92% to $0.31 in 2022, then plummeted by 58.92% to $0.13 in 2023.
  • The last three reported values for Debt to Equity were $0.13 (Q3 2023), $0.29 (Q2 2023), and $0.27 (Q1 2023) per Business Quant data.